Collaborative Medicinal Development, LLC (CMD) is focused on creating innovative therapeutics aimed at treating neurodegenerative diseases and cancer. The company is actively developing novel small molecule ferroptosis inhibitors, which represent a first-in-class approach to combat conditions such as Alzheimer’s, Huntington’s, and Parkinson’s diseases. Ferroptosis is a specific form of cell death characterized by the accumulation of lipid peroxides, which is influenced by the interplay of amino acid, lipid, and iron metabolism. CMD's research highlights the critical role of the enzyme glutathione peroxidase 4 (GPX4) in regulating ferroptosis, as its inactivation leads to increased lipid peroxidation and subsequent cell death. The company aims to leverage this understanding to develop therapeutics that can effectively target and inhibit ferroptosis in affected neuronal cells.

CMD's approach includes both the invention of new chemical entities and the licensing of promising leads from external sources. The company has made significant progress in developing small molecules that not only inhibit ferroptosis but also demonstrate metabolic stability, which is crucial for therapeutic efficacy. Ongoing preclinical pharmacology and ADME (Absorption, Distribution, Metabolism, and Excretion) studies are being conducted to further evaluate these compounds. By focusing on the unique mechanisms of ferroptosis and its implications in neurodegenerative diseases, CMD is positioning itself at the forefront of therapeutic innovation in this critical area of medicine.

United States

Collaborative Medicinal Development LLC is a company based out of 184 Bulkley Avenue, Sausalito, California, United States.

Collaborative Medicinal Development

Company Details